Blog

Introduction to the Onychomycosis Severity Index (OSI) Onychomycosis, a common disease of the nail unit caused by dermatophytes, nondermatophyte molds, and yeasts, has a prevalence of approximately 10-20% worldwide. Currently no standardized system exists to clinically grade the severity of onychomycotic nail disease. Such a scale is necessary for clinical trial inclusion criteria, for critical evaluation of treatment choice, and to help predict therapeutic outcome. Having quantitative numbers can also assist when discussing these factors with patients and other clinicians. Inconsistences in onychomycotic grading systems can also lead to confusion about interpretation of efficacy. Recently, in a trial of ciclopirox…

Read More

ToeFX is driven by innovation. The vision of our science team is to create the world’s most effective foot care treatments. As such, we continually conduct research to improve our understanding of one of the world’s most stubborn and prevalent infections – onychomycosis.  In order to treat even the most complex cases of onychomycosis, we need to take a holistic treatment approach – from diagnostics to follow-up.  One area of intense focus for ToeFX is diagnostics. We are excited to announce that starting this autumn, we are launching a new collaboration with Professor Jianping Xu from the McMaster University. The…

Read More

ToeFX co-founder Dr Irit Van-Ham enjoys cycling….here she weighs in on the commonalities between cycling and toenail fungus. According to recent studies, some 6-20% of people worldwide suffer from fungal nail infections or onychomycosis. It’s even more common in seniors: it affects 50% of those over 70. This infection can have serious health implications. When the toenail (big toe) breaks off from the skin, bacteria can enter the wound, making the area more susceptible to infection. But what has cycling got to do with toenail fungus? Here are some common features: 1) It does not take a lot to grow:…

Read More

We are excited at being selected to be in this year’s cohort of 2021 Capital Access Advisory Program from The Ontario Bioscience Innovation Organization. Proud to be recognized as a high potential health science company and looking forward to continuing the momentum with many more innovative solutions. The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce its 2021 Capital Access Advisory Program (CAAP®) and the high-potential health science companies in this year’s cohort.

Read More

On March 24, ToeFX took home the grand prize in the Synapse Competition, Ontario’s premier life science pitch competition. The Synapse Competition is dedicated to fostering the commercialization of innovation in the life science sector. Delivered by Innovation Factory, in collaboration with the Synapse Consortium, the competition supports innovators, scientists and researchers to launch their ideas to market, increase revenues, attract investment, and create jobs. “The ToeFX team is delighted and proud to have been selected as the winner of the Synapse Life Science Competition 2021. This recognition will propel us forward as we strive to become the global standard…

Read More